Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unlocking Bevacizumab's Potential, rCBVmax as a Predictive Biomarker for Enhanced Survival in Glioblastoma IDH-Wildtype Patients

  • Álvarez-Torres, María del Mar
  • Balañá, Carmen|||0000-0003-0771-0390
  • Fuster-Garcia, Elies|||0000-0002-0716-8960
  • Puig, Josep|||0000-0003-2791-6599
  • García Gómez, Juan Miguel|||0000-0002-3851-1557
Background: Aberrant vascular architecture and angiogenesis are hallmarks of glioblastoma IDH-wildtype, suggesting that these tumors are suitable for antiangiogenic therapy. Bevacizumab was FDA-approved in 2009 following promising results in two clinical trials. However, its use for recurrent glioblastomas remains a subject of debate, as it does not universally improve patient survival. Purposes: In this study, we aimed to analyze the influence of tumor vascularity on the benefit provided by BVZ and propose preoperative rCBVmax at the high angiogenic tumor habitat as a predictive biomarker to select patients who can benefit the most. Methods: Clinical and MRI data from 106 patients with glioblastoma IDH-wildtype have been analyzed. Thirty-nine of them received BVZ, and the remaining sixty-seven did not receive a second-line treatment. The ONCOhabitats method was used to automatically calculate rCBV. Results: We found a median survival from progression of 305 days longer for patients with moderate vascular tumors who received BVZ than those who did not receive any second-line treatment. This contrasts with patients with high-vascular tumors who only presented a median survival of 173 days longer when receiving BVZ. Furthermore, better responses to BVZ were found for the moderate-vascular group with a higher proportion of patients alive at 6, 12, 18, and 24 months after progression. Conclusions: We propose rCBVmax as a potential biomarker to select patients who can benefit more from BVZ after tumor progression. In addition, we propose a threshold of 7.5 to stratify patients into moderate- and high-vascular groups to select the optimal second-line treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multikinase Treatment of Glioblastoma, Evaluating the Rationale for Regorafenib

  • Muñoz-Mármol, Ana Maria|||0000-0003-1008-7763
  • Meléndez, Bárbara
  • Hernández, Ainhoa|||0000-0003-4678-6662
  • Sanz, Carolina
  • Domènech Viñolas, Marta|||0000-0003-4827-9170
  • Arpí-Llucia, Oriol
  • Gut, Marta|||0000-0002-4063-7159
  • Esteve, Anna|||0000-0002-1962-971X
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Parra, Genis
  • Carrato, Cristina|||0000-0002-1953-8287
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Pineda, Estela|||0000-0003-2128-747X
  • Alameda, Francesc|||0000-0002-7302-6901
  • de la Iglesia, Nuria|||0000-0002-1083-7715
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Estival, Anna|||0000-0002-2788-9159
  • Balañá, Carmen|||0000-0003-0771-0390
For a targeted drug to be effective, the target must be present. To determine if this condition was met for regorafenib in glioblastoma, we analyzed 46 genes encoding protein kinases (PKs) inhibited by regorafenib in preclinical studies. We further focused on a subset of 18 genes encoding PKs inhibited by regorafenib at clinically achievable concentrations, which-together with the anti-angiogenetic activity of regorafenib-constituted the rationale for the REGOMA and AGILE trials. Oncogenic/likely oncogenic mutations, gene amplification, fusions, and/or gene overexpression indicated a potential regorafenib target. Thirty-four (33%) and twenty-six (25.2%) patients harbored at least one such alteration in the 46- and 18-gene sets, respectively. However, these results may overestimate the effectiveness of regorafenib due to its difficulty in penetrating the blood-brain barrier to reach the target. Future use of multi-target drugs should be guided by a thorough understanding of target presence and the drug's ability to reach the target. We explored the rationale for treating glioblastoma (GBM) with regorafenib. In 103 newly diagnosed GBM patients, we assessed mutations, copy number variants (CNVs), fusions, and overexpression in 46 genes encoding protein kinases (PKs) potentially targeted by regorafenib or its metabolites and performed a functional enrichment analysis to assess their implications in angiogenesis. We analyzed regorafenib's binding inhibitory activity and target affinity for these 46 PKs and focused on a subset of 18 genes inhibited by regorafenib at clinically achievable concentrations and on 19 genes involved in angiogenesis. Putative oncogenic alterations were defined as oncogenic/likely oncogenic mutations, oncogenic fusions, CNVs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The C250T Mutation of TERTp Might Grant a Better Prognosis to Glioblastoma by Exerting Less Biological Effect on Telomeres and Chromosomes Than the C228T Mutation

  • Gorría, Teresa
  • Crous, Carme
  • Pineda, Estela|||0000-0003-2128-747X
  • Hernandez, Ainhoa
  • Domènech Viñolas, Marta|||0000-0003-4827-9170
  • Sanz, Carolina
  • Jares, Pedro
  • Muñoz-Mármol, Ana María
  • Arpí Lluciá, Oriol|||0000-0002-5578-2092
  • Melendez, Bárbara
  • Gut, Marta|||0000-0002-4063-7159
  • Esteve, Anna|||0000-0002-1962-971X
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Parra, Genis
  • Alameda, Francesc|||0000-0002-7302-6901
  • Carrato, Cristina|||0000-0002-1953-8287
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • de la Iglesia, Nuria|||0000-0002-1083-7715
  • Balañá, Carmen|||0000-0003-0771-0390
In our glioblastoma patients treated with standard therapy, the TERTp C250T mutation occurred less frequently than the C228T mutation. Patients with the C250T mutation had better prognosis than those with either TERTp -wt or TERTp C228T mutations, even when adjusted for key glioblastoma prognostic factors. This may be due to the lesser involvement of the C250T mutation in telomere- and chromosome-related pathways, as evidenced by the results of a gene enrichment analysis adjusted for MGMTp methylation status: TERTp C250T was differentially enriched compared to TERTp -wt and C228T. There were no differences according to TERTp mutation status in the mutations or copy number variants of other genes commonly present in glioblastoma. The biological pathways by which TERTp and MGMTp exert their effects are independent. The aim of this study was to determine how TERTp mutations impact glioblastoma prognosis. Materials and Methods: TERTp mutations were assessed in a retrospective cohort of 258 uniformly treated glioblastoma patients. RNA-sequencing and whole exome sequencing results were available in a subset of patients. Results: Overall, there were no differences in outcomes between patients with mutated TERTp -wt or TERTp. However, we found significant differences according to the type of TERTp mutation. Progression-free survival (mPFS) was 9.1 months for those with the C250T mutation and 7 months for those with either the C228T mutation or TERTp -wt (p = 0.016). Overall survival (mOS) was 21.9 and 15 months, respectively (p = 0.026). This differential effect was more pronounced in patients with MGMTp methylation (mPFS: p = 0.008; mOS: p = 0.021). Multivariate analysis identified the C250T mutation as an independent prognostic factor for longer mOS (HR 0.69; p = 0.044). We found no differences according to TERTp mutation status in molecular alterations common in glioblastoma, nor in copy number variants in genes related to alternative lengthening of telomeres. Nevertheless, in the gene enrichment analysis adjusted for MGMTp methylation status, some Reactome gene sets were differentially enriched, suggesting that the C250T mutation may exert a lesser effect on telomeres or chromosomes. Conclusions: In our series, patients exhibiting the C250T mutation had a more favorable prognosis compared to those with either TERPp -wt or TERTp C228T mutations. Additionally, our findings suggest a reduced involvement of the C250T mutation in the underlying biological mechanisms related to telomeres.